EMERGENT BIOSOLUTIONS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.92 USD | -1.54% |
|
-5.88% | -20.00% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,785 | 4,749 | 2,339 | 589.2 | 124.5 | 100.6 | - |
| Enterprise Value (EV) 1 | 3,428 | 5,002 | 2,603 | 1,352 | 873 | 256.3 | 502.2 |
| P/E ratio | 51.9 x | 15.8 x | 10.2 x | -2.64 x | -0.16 x | -1.19 x | 1.32 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2.52 x | 3.05 x | 1.3 x | 0.53 x | 0.12 x | 0.09 x | 0.09 x |
| EV / Revenue | 3.1 x | 3.22 x | 1.45 x | 1.21 x | 0.83 x | 0.23 x | 0.45 x |
| EV / EBITDA | 12.3 x | 7.94 x | 5.03 x | 51.8 x | -39.1 x | 3.42 x | - |
| EV / FCF | 33.9 x | 12.7 x | 27.1 x | -9.02 x | -3.39 x | -10.3 x | - |
| FCF Yield | 2.95% | 7.9% | 3.69% | -11.1% | -29.5% | -9.75% | - |
| Price to Book | 2.55 x | 3.29 x | 1.38 x | 0.43 x | 0.19 x | 0.12 x | 0.1 x |
| Nbr of stocks (in thousands) | 51,624 | 52,999 | 53,799 | 49,888 | 51,884 | 52,391 | - |
| Reference price 2 | 53.95 | 89.60 | 43.47 | 11.81 | 2.400 | 1.920 | 1.920 |
| Announcement Date | 2/20/20 | 2/18/21 | 2/24/22 | 2/27/23 | 3/6/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,106 | 1,555 | 1,793 | 1,121 | 1,049 | 1,099 | 1,126 |
| EBITDA 1 | 279.7 | 630.4 | 517.6 | 26.1 | -22.3 | 75 | - |
| EBIT 1 | 114.1 | 433.8 | 352.6 | -172.7 | -726.4 | 0.9673 | 126.9 |
| Operating Margin | 10.32% | 27.89% | 19.67% | -15.41% | -69.23% | 0.09% | 11.26% |
| Earnings before Tax (EBT) 1 | 77.4 | 407.2 | 314.4 | -221.7 | -731.2 | -65.84 | 89 |
| Net income 1 | 54.5 | 305.1 | 230.9 | -223.8 | -760.5 | -83.1 | 66.75 |
| Net margin | 4.93% | 19.62% | 12.88% | -19.97% | -72.48% | -7.56% | 5.93% |
| EPS 2 | 1.040 | 5.670 | 4.270 | -4.470 | -14.85 | -1.614 | 1.455 |
| Free Cash Flow 1 | 101.1 | 395 | 96.1 | -149.9 | -257.9 | -25 | - |
| FCF margin | 9.14% | 25.4% | 5.36% | -13.37% | -24.58% | -2.27% | - |
| FCF Conversion (EBITDA) | 36.15% | 62.66% | 18.57% | - | - | - | - |
| FCF Conversion (Net income) | 185.5% | 129.47% | 41.62% | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 2/20/20 | 2/18/21 | 2/24/22 | 2/27/23 | 3/6/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 329 | 723.2 | 307.5 | 242.7 | 240 | 330.7 | 165.1 | 337.9 | 270.5 | 276.6 | 224.5 | 244.5 | 268 | 288 |
| EBITDA 1 | -3.3 | 347.9 | 36 | -28.8 | -15.2 | 34.2 | -100.8 | 55.9 | 19.8 | 3.4 | -5.5 | 9.5 | 28 | 43 |
| EBIT 1 | -34.7 | 277.4 | 6.4 | -72 | -42 | -65.1 | -148.1 | 13.8 | -242.1 | -43.8 | -40.5 | -30.5 | -17 | -7 |
| Operating Margin | -10.55% | 38.36% | 2.08% | -29.67% | -17.5% | -19.69% | -89.7% | 4.08% | -89.5% | -15.84% | -18.04% | -12.47% | -6.34% | -2.43% |
| Earnings before Tax (EBT) 1 | -45.5 | 267.5 | -3.8 | -82.8 | -63.9 | -71.2 | -161.1 | -250.2 | -265.9 | -54.5 | -58 | -48 | -34.5 | -24.5 |
| Net income 1 | -32.7 | 189.3 | -3.7 | -56.4 | -75.7 | -88 | -183 | -261.3 | -263.4 | -49.5 | -55.5 | -45.5 | -32 | -22 |
| Net margin | -9.94% | 26.18% | -1.2% | -23.24% | -31.54% | -26.61% | -110.84% | -77.33% | -97.38% | -17.9% | -24.72% | -18.61% | -11.94% | -7.64% |
| EPS 2 | -0.6100 | 3.500 | -0.0700 | -1.130 | -1.520 | -1.760 | -3.650 | -5.150 | -5.080 | -0.9500 | -1.070 | -0.8800 | -0.6100 | -0.4200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 2/24/22 | 4/28/22 | 8/1/22 | 11/8/22 | 2/27/23 | 5/9/23 | 8/8/23 | 11/8/23 | 3/6/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | 643 | 254 | 265 | 763 | 749 | 156 | 402 |
| Net Cash position 1 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 2.3 x | 0.4024 x | 0.5114 x | 29.24 x | -33.57 x | 2.077 x | - |
| Free Cash Flow 1 | 101 | 395 | 96.1 | -150 | -258 | -25 | - |
| ROE (net income / shareholders' equity) | 14.5% | 33.4% | 21.2% | -7.46% | -31.3% | 15.8% | 21% |
| ROA (Net income/ Total Assets) | 6.68% | 16.3% | 11.1% | -3.65% | -12.8% | 6.03% | 9.44% |
| Assets 1 | 815.9 | 1,875 | 2,071 | 6,126 | 5,947 | -1,379 | 706.9 |
| Book Value Per Share 2 | 21.10 | 27.30 | 31.60 | 27.60 | 12.40 | 16.60 | 18.50 |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | 86.9 | 141 | 225 | 116 | 51.6 | 30 | - |
| Capex / Sales | 7.86% | 9.07% | 12.55% | 10.33% | 4.92% | 2.73% | - |
| Announcement Date | 2/20/20 | 2/18/21 | 2/24/22 | 2/27/23 | 3/6/24 | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.92
USD
Average target price
5
USD
Spread / Average Target
+160.42%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.00% | 101M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- EBS Stock
- Financials Emergent BioSolutions Inc.
